LU Bio, partially owned by Lund University in Sweden, invests in early-stage bioscience inventions, providing capital and industrial expertise to enable fast and efficient development. The firm has invested in companies like Cytoguide and ProNoxis, and aims to bridge the gap between research and commercialization in the pharmaceutical field. Founded in 2007, LU Bio is based in Lund, Sweden.